References

Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2024 · External reference

Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries

10.1016/s0140-6736(17)33326-3 · 2018 · External reference

Epidemiological review of gastric cancer in India

2012 · External reference

D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer

10.1056/nejmoa0707035 · 2008 · External reference

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

10.1056/nejmoa010187 · 2001 · External reference

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial

10.1016/s0140-6736(11)61873-4 · 2012 · External reference

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

10.1056/nejmoa055531 · 2006 · External reference

Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial

10.1200/jco.2010.33.0597 · 2011 · External reference

Perioperative FLOT versus ECF/ECX for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4)

10.1016/s0140-6736(18)32557-1 · 2019 · External reference

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

10.1056/nejmoa072252 · 2007 · External reference

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer–pooled analysis from three multicenter, randomized, controlled trials using individual patient data

10.1200/jco.2004.08.154 · 2004 · External reference

Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group

10.1200/jco.2006.06.8429 · 2006 · External reference

Phase II trial of fluorouracil, leucovorin, oxaliplatin and docetaxel in patients with locally advanced gastric cancer

2013 · External reference

Immunogenic cell death in cancer and infectious disease

10.1038/nri.2016.107 · 2017 · External reference

Preoperative chemoradiotherapy for esophageal or junctional cancer

10.1056/nejmoa1112088 · 2012 · External reference

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction

10.1200/jco.2008.17.0506 · 2009 · External reference

Neo-AEGIS: perioperative chemotherapy versus neoadjuvant chemoradiotherapy in esophageal and junctional adenocarcinoma

2023 · External reference

Perioperative chemotherapy or preoperative chemoradiotherapy in esophageal cancer

10.1056/nejmoa2409408 · 2025 · External reference

Preoperative chemoradiotherapy for resectable gastric cancer

10.1056/nejmoa2405195 · 2024 · External reference

The two histological main types of gastric carcinoma

10.1111/apm.1965.64.1.31 · 1965 · External reference

Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes

10.1038/nm.3850 · 2015 · External reference

Comprehensive molecular characterization of gastric adenocarcinoma

10.1038/nature13480 · 2014 · External reference

Signet ring cell histology is associated with poor response to neoadjuvant therapy in gastric cancer

2014 · External reference

Mismatch repair deficiency, microsatellite instability and survival in gastric cancer

2017 · External reference

Comparison of gastric cancer survival following R0 resection in the United States and Korea

2015 · External reference

PRODIGY: neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 in resectable advanced gastric cancer

10.1200/jco.20.02914 · 2021 · External reference

Perioperative chemotherapy with S-1 and oxaliplatin in locally advanced gastric cancer: RESOLVE trial

2019 · External reference

Neoadjuvant chemotherapy for type 4 and large type 3 gastric cancer (JCOG0501)

2020 · External reference

Results of the observational prospective RealFLOT study

10.1186/s12885-021-08768-7 · 2021 · External reference

Real-world outcomes of FLOT in gastric and gastroesophageal junction cancer

2020 · External reference

An analysis of tolerance and early survival outcomes with perioperative modified FLOT in gastric cancers

10.1055/s-0041-1733349 · 2022 · External reference

Perioperative modified FLOT versus EOX in locally advanced resectable gastric and gastro-oesophageal junction adenocarcinoma: results of a matched-pair analysis

10.1007/s12029-022-00867-3 · 2023 · External reference

Perioperative chemotherapy with FLOT versus EOX/ECF in resectable gastric or gastroesophageal junction adenocarcinoma: safety and response data from India

2019 · External reference

Epirubicin, oxaliplatin, and capecitabine is just as 'MAGIC'al as epirubicin, cisplatin, and fluorouracil perioperative chemotherapy in locally advanced gastric cancer

10.4103/0973-1482.146122 · 2014 · External reference

Immunological aspects of cancer chemotherapy

2013 · External reference

Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study

10.1016/s1470-2045(23)00541-7 · 2024 · External reference

Perioperative durvalumab in gastric and gastroesophageal junction cancer

10.1056/nejmoa2503701 · 2025 · External reference

DANTE: atezolizumab with perioperative FLOT in resectable gastric and gastroesophageal junction cancer

2022 · External reference

ATTRACTION-5: adjuvant nivolumab plus chemotherapy after D2 gastrectomy

2023 · External reference

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation for Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

10.1016/j.annonc.2024.10.829 · 2025 · External reference

Minimal residual disease detection using a plasma-only circulating tumor DNA assay in gastrointestinal cancers

2021 · External reference

White blood cell and cell-free DNA analyses for detection of residual disease in gastric cancer

10.1038/s41467-020-14310-3 · 2020 · External reference

Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer

2016 · External reference

Epidemiology of gastric cancer: global trends, risk factors and prevention

2019 · External reference

Real-world long-term outcomes with perioperative EOX in D2 gastrectomy: a meaningful look while we switch to FLOT-4

10.1007/s12029-020-00358-3 · 2020 · External reference

Perioperative FLOT vs EOX regimen and non-metastatic gastric carcinoma survival outcomes: real-world data from a tertiary cancer centre, India

2025 · External reference